×

Helus Pharma’s psychedelic depression drug succeeds in late-stage study

By Thomson Reuters Nov 16, 2026 | 6:09 AM

Nov 16 (Reuters) – Helus Pharma said on Monday ​its experimental ‌psychedelic drug showed statistically significant improvement in depression symptoms ‌compared ​with ⁠placebo in ⁠a late-stage trial in patients with major depressive disorder.

The ​study enrolled 222 adults ⁠with ⁠moderate to severe ​major depression.

After six ​weeks, patients on ‌HLP003 improved by 19.5 points on a ⁠standard depression scale, while patients on placebo ⁠improved ‌by 11.9 ⁠points, the ​company ‌said.

However, shares fell ​20% in ⁠premarket trading.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Jonathan ​Ananda)